Robert Pelzer - Net Worth and Insider Trading

Robert Pelzer Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Robert Pelzer owns 2 companies in total, including Sierra Oncology Inc (SRRA) , and Neoleukin Therapeutics Inc (NLTX) .

Click here to see the complete history of Robert Pelzer’s form 4 insider trades.

Insider Ownership Summary of Robert Pelzer

Ticker Comapny Transaction Date Type of Owner
SRRA Sierra Oncology Inc 2015-07-15 director
NLTX Neoleukin Therapeutics Inc 2014-03-06 director

Robert Pelzer Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Robert Pelzer Ownership Network

Ownership Network List of Robert Pelzer

No Data

Ownership Network Relation of Robert Pelzer

Insider Network Chart

Robert Pelzer Owned Company Details

What does Sierra Oncology Inc do?

Who are the key executives at Sierra Oncology Inc?

Robert Pelzer is the director of Sierra Oncology Inc. Other key executives at Sierra Oncology Inc include director & 10 percent owner Vivo Opportunity Fund Holdings, L.p. , Chief Reg & Tech Ops Officer William D. Turner , and General Counsel Mary Christina Thomson .

Sierra Oncology Inc (SRRA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sierra Oncology Inc (SRRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sierra Oncology Inc (SRRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sierra Oncology Inc (SRRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Sierra Oncology Inc Insider Transactions

No Available Data

Robert Pelzer Mailing Address

Above is the net worth, insider trading, and ownership report for Robert Pelzer. You might contact Robert Pelzer via mailing address: C/o Idenix Pharmaceuticals, Inc., 60 Hampshire Street, Cambridge Ma 02139.

Discussions on Robert Pelzer

No discussions yet.